Truist Financial Sticks to Its Buy Rating for POINT Biopharma Global (PNT)

Truist Financial analyst Nicole Germino maintained a Buy rating on POINT Biopharma Global (PNTResearch Report) today and set a price target of $14.00. The company’s shares opened today at $5.96.

Germino covers the Healthcare sector, focusing on stocks such as POINT Biopharma Global, Assembly Biosciences, and Fusion Pharmaceuticals. According to TipRanks, Germino has an average return of -25.3% and a 20.00% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for POINT Biopharma Global with a $18.43 average price target, implying a 209.23% upside from current levels. In a report released today, Berenberg Bank also maintained a Buy rating on the stock with a $18.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $10.98 and a one-year low of $4.25. Currently, POINT Biopharma Global has an average volume of 848K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Therapeutics Acquisition Corp is a blank check company.

Read More on PNT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More